Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
A Systematic Analysis for the Global Burden of Disease Study 2019

Global Burden of Disease 2019 Cancer Collaboration


**OBJECTIVE** To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019.

**EVIDENCE REVIEW** The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs).

**FINDINGS** In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles.

**CONCLUSIONS AND RELEVANCE** The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.

**Corresponding Author:** Jonathan M. Kocarnik, PhD, MPH, Institute for Health Metrics and Evaluation, Population Health Building/Hans Rosling Center, University of Washington, Box #351615, 3980 15th Ave NE, Seattle, WA 98195 (jkocarnik@uw.edu).

Published online December 30, 2021.
Cancers are a major contributor to disease burden worldwide, and projections forecast that global cancer burden will continue to grow for at least the next 2 decades.1-4 The United Nations (UN) Sustainable Development Goals (SDGs) recognize the need for reducing cancer burden as part of target 3.4, stating “By 2030, reduce by one third premature mortality from noncommunicable diseases [NCDs] through prevention and treatment and promote mental health and well-being.”5 Most countries will need to accelerate their efforts to reduce NCD burden, including cancer, to meet this SDG target.6-8 Increasing the pace of progress will be particularly critical given the ongoing COVID-19 pandemic, which has led to delays and disruptions in cancer screenings, diagnosis, and treatment around the world.9-12

The importance of prevention and control of NCDs, including cancer, was emphasized by the third UN High-Level Meeting on NCDs in 201813 and the UN High-Level Meeting on Universal Health Coverage in 2019.14,15 World Health Organization initiatives that are focused on breast cancer,16 cervical cancer,17 and childhood cancer18 are valuable efforts toward reducing global cancer burden in combination with national-level cancer control planning and implementation. Global and local efforts require comprehensive assessments of cancer burden, information that may be sparse or unavailable in some countries.19

The Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2019 (GBD 2019) framework enables the comparable assessment of cancer burden across locations and time in terms of cancer incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs).20 Estimates of YLLs, YLDs, and DALYs complement incidence and mortality estimates by incorporating morbidity and mortality contributions to total cancer burden over the lifetime. Because GBD 2019 estimated disease burden across a mutually exclusive and collectively exhaustive hierarchy of diseases and injuries, cancer burden can also be systematically compared with and ranked against other causes of disease burden. Together, these qualities help GBD 2019 provide a comprehensive picture of variation in cancer burden that can potentially inform cancer control planning.

In this article, we present results for 29 cancer groups from the GBD 2019 study, globally and for 204 countries and territories, from 2010 through 2019. Results are also provided by quintiles of the Sociodemographic Index (SDI), a summary indicator of social and economic development that allows for analyses of disease burden patterns across different resource contexts.20,21 These estimates update results from the GBD 2017 study22 and supersede published estimates from previous GBD iterations.22-25

**Methods**

This section provides an overview of GBD 2019 cancer estimation methods. Additional detail is provided in the GBD 2019 summary publications,20,21,26 as well as in the eAppendix, eFigures 1 to 15, and eTables 1 to 18 in the Supplement. This study is compliant with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement (eTable 13 in the Supplement).27 The University of Washington institutional review board committee approved GBD 2019, and informed consent was waived because of the use of deidentified data. This article was produced as part of the GBD Collaborator Network and in accordance with the GBD Protocol (http://www.healthdata.org/gbd/about/protocol).

**Key Points**

**Question** What was the burden of cancer globally and across Sociodemographic Index (SDI) groupings in 2019, and how has incidence, morbidity, and mortality changed since 2010?

**Findings** In this systematic analysis, there were 23.6 million new global cancer cases in 2019 (17.2 million when excluding those with nonmelanoma skin cancer), 10.0 million cancer deaths, and an estimated 250 million disability-adjusted life years estimated to be due to cancer; since 2010, these represent increases of 26.3%, 20.9%, and 16.0%, respectively. Absolute cancer burden increased in all SDI quintiles since 2010, but the largest percentage increases occurred in the low and low-middle SDI quintiles.

**Meanings** The study results suggest that increased cancer prevention and control efforts are needed to equitably address the evolving and increasing burden of cancer across the SDI spectrum.
with lower values representing lower development. While SDI values may change over time, for consistency of comparison, countries were grouped into quintiles according to their SDI values in 2019 (eTable 2 and eFigure 1 in the Supplement). These quintiles were termed low, low-middle, middle, high-middle, and high. More details are provided in the eAppendix in the Supplement, including the population and SDI bounds for each quintile.

Data Sources and Processing
Cancer estimation in GBD 2019 used 929,193 cancer-, location-, and year-specific sources of data, of which 767,514 (82.6%) were from vital registration systems, 155,542 (16.7%) from cancer registries, and 61,37 (0.7%) from verbal autopsy reports (eTable 1 in the Supplement). The cancers presented in this analysis include malignant neoplasms or cancer as defined by the International Statistical Classification of Diseases and Related Health Problems, Ninth Revision (ICD-9) codes 140 to 209,28 or Tenth Revision (ICD-10) codes C00 to C96.29 Incidence and mortality data with these ICD codes are mapped to GBD cancer causes20 (eAppendix and eTables 3-5 in the Supplement). One processing update for GBD 2019 was the remapping of deaths coded to ICD-10 code C22.9; because this code includes unspecified primary or secondary liver cancer, a subset of these deaths were redistributed to various other cancers that metastasize to the liver.20,30,31 Kaposi sarcoma was not estimated because deaths were primarily redistributed to be of HIV/AIDS (eAppendix in the Supplement). The GBD NMSC estimates included squamous cell carcinoma and basal cell carcinoma. Because NMSC reporting was incomplete in many cancer registries,32 GBD 2019 additionally incorporated data from the literature and clinical sources to estimate NMSC burden (eAppendix in the Supplement).

Modeling Process
The GBD cancer mortality and YLL estimation process included 2 primary steps (eFigure 2 in the Supplement), beginning with the estimation of cancer MIRs, which provide an association between mortality and incidence estimation, maximizing data availability. The MIRs were modeled using a space-time Gaussian process regression approach26 (MIR methods are described in the eAppendix in the Supplement) using matched incidence and mortality data from cancer registries (eTable 6 in the Supplement) and the GBD-estimated health care access and quality index33 as a covariate. These estimated MIRs were then used to convert cancer registry incidence data into inputs for mortality modeling.

Estimating cancer mortality was the second step. The GBD 2019 study used a Cause of Death Ensemble model (CODEm) approach that combined data from vital registration systems, cancer registries, and verbal autopsy reports to estimate mortality across several submodels.34 Covariates provided for potential inclusion in the submodels of the ensemble, such as smoking prevalence or alcohol use, can be found in the eAppendix and eTables 7 and 8 in the Supplement. Ensemble model construction and performance was evaluated through out-of-sample predictive validity tests (eTable 9 in the Supplement). For each cancer, sex-specific CODEm models generated mortality estimates across locations, years, and age groups. These cancer mortality estimates were then scaled to align with the total mortality for all causes of death, which was separately estimated in GBD 2019 (eTable 10 in the Supplement).21 To estimate YLLs, a standard age-specific GBD life expectancy was applied to mortality estimates by age group (eAppendix in the Supplement).20

The GBD cancer incidence and YLD estimation process included 2 additional steps (eFigure 3 in the Supplement), starting with estimating incidence. Incidence was estimated by taking mortality estimates from the second step described previously and dividing by MIR estimates from the first step described previously for each cancer type, sex, location, year, and 5-year age group. Additional information can be found in the eAppendix in the Supplement.

Next, YLDs were estimated by combining prevalence estimates with disability weights associated with various phases of cancer survival. To estimate 10-year cancer prevalence, survival curves estimated from MIRs were combined with GBD-estimated background mortality and applied to incidence estimates. Additional information regarding survival and prevalence estimation can be found in the eAppendix and eFigure 3 in the Supplement. These 10-year prevalence estimates were then partitioned into 4 sequelae according to the expected person-time spent in these 4 phases of cancer survival: (1) diagnosis/treatment, (2) remission, (3) metastatic/disseminated, and (4) terminal (eTable 11 in the Supplement). Each sequela prevalence was multiplied by a sequela-specific disability weight that represented the magnitude of health loss (eTable 12 in the Supplement).20 For 5 cancer types (bladder, breast, colorectal, larynx, and prostate cancer), the total prevalence additionally included lifetime prevalence of procedure-related disability (eg, laryngectomy due to larynx cancer). These procedure-related prevalence estimates were modeled in the Bayesian meta-regression tool DisMod-MR, version 2.1,20 using medical records data on the proportion of patients with cancer who underwent these procedures and the estimated number of 10-year survivors (eAppendix in the Supplement). These procedure-related prevalence estimates were then multiplied by procedure-specific disability weights (eTable 12 in the Supplement). Total cancer-specific YLDs were estimated by summing across these sequelae. Finally, DALYs were estimated as the sum of YLDs and YLLs.20

Reporting Standards
All rates are reported per 100,000 person-years. Annualized rates of change from 2010 to 2019 represent the mean percentage change per year during this period (eAppendix in the Supplement). The GBD world population standard was used to calculate age-standardized rates (eAppendix in the Supplement).21 For all estimates, 95% uncertainty intervals (UIs) are reported. Uncertainty was propagated through each step of the cancer estimation process, with UIs representing the 2.5th and 97.5th percentiles of the distribution of 1000 draws at each step (eAppendix in the Supplement).20

Results are reported for 29 cancer groups, 204 countries and territories, and 5 SDI quintiles from 2010 to 2019. These estimates, as well as extended years (1990-2019), additional cancer groups, national and subnational locations, sex-
specific estimates, and additional age groups are available from online resources (https://vizhub.healthdata.org/gbd-compare/ and http://ghdx.healthdata.org/gbd-results-tool).

Data processing and analyses were conducted using Python, version 3.7.0 (Python Software Foundation); Stata, version 15.1 (StataCorp); and R, version 3.4.1 (R Foundation). Code is available at https://ghdx.healthdata.org/gbd-2019/code.

Results

Global Estimates of Total Cancers and Cancer-Specific Burden in 2019

Across 204 countries and territories, there were 23.6 million (95% UI, 22.2-24.9 million) incident cancer cases and 10.0 million (95% UI, 9.36-10.6 million) deaths in 2019 (Table 1). Excluding NMSC, there were an estimated 17.2 million (95% UI, 15.9-18.5 million) incident cancer cases and 9.97 million (95% CI, 9.31-10.5 million) deaths (Table 1).

Globally, cancers were estimated to cause 250 million (95% UI, 235-264 million) DALYs in 2019 (eTable 15 in the Supplement). Of the total global DALYs, 96.9% (95% UI, 96.0%-97.7%) came from YLLs, whereas 3.1% (95% UI, 2.3%-4.0%) came from YLDs (eTable 14 and eFigure 4 in the Supplement). Among the 22 groups of diseases and injuries in level 2 of the GBD cause hierarchy (Figure 1), total cancer was the second-highest cause of DALYs, deaths, and YLLs behind cardiovascular diseases (Table 2; eTable 15 in the Supplement). As such, cancer had greater overall and fatal burden globally in 2019 than other major groups of diseases in the GBD, such as maternal and neonatal disorders, musculoskeletal disorders, and respiratory infections and tuberculosis (Figure 1).

The 5 leading causes of cancer-related DALYs for both sexes combined (Figure 2), excluding other malignant neoplasms, were tracheal, bronchus, and lung (TBL) cancer, with 18.3% (95% UI, 17.5%-19.1%) of total cancer-related DALYs; colon and rectum cancer (CRC), with 9.7% (95% UI, 9.4%-10.0%); stomach cancer, with 8.9% (8.6%-9.3%); breast cancer, with 8.2% (7.8%-8.7%); and liver cancer, with 5.0% (4.8%-5.3%).

Tracheal, bronchus, and lung cancer were estimated to cause 45.9 million (95% UI, 42.3-49.3 million) DALYs in 2019; of these, 98.8% (95% UI, 98.5%-99.1%) came from YLLs and just 1.2% (95% UI, 0.9%-1.5%) from YLDs (eTable 14 and eFigure 4 in the Supplement). In 2019, there were 2.04 million (95% UI, 1.88-2.19 million) deaths due to TBL cancer and 2.26 million (95% UI, 2.07-2.45 million) incident TBL cases (Table 1). Tracheal, bronchus, and lung cancer was the leading cause of cancer incidence and mortality in 58 and 119 countries and territories, respectively, for males (eFigures 5 and 6 in the Supplement), and 1 and 27 countries, respectively, for females (eFigures 7 and 8 in the Supplement).

Colon and rectum cancer were estimated to cause 24.3 million (95% UI, 22.6-25.7 million) DALYs in 2019; of these, 95.6% (95% UI, 94.4%-96.8%) came from YLLs and 4.4% (95% UI, 3.2%-5.6%) from YLDs (eTable 14 and eFigure 4 in the Supplement). In 2019, there were 1.09 million (95% UI, 1.00-1.15 million) deaths due to CRC and 2.17 million (95% UI, 2.00-2.34 million) incident CRC cases (Table 1). Colon and rectum cancer was the leading cause of cancer incidence and mortality in 1 country and 9 countries, respectively, for females (eFigures 7 and 8 in the Supplement) and of cancer incidence for 11 countries in males (eFigure 5 in the Supplement).

Stomach cancer was estimated to cause an estimated 22.2 million (95% UI, 20.3-24.1 million) DALYs in 2019; of these, 98.4% (95% UI, 98.0%-98.9%) came from YLLs and 1.6% (95% UI, 1.1%-2.0%) from YLDs (eTable 14 and eFigure 4 in the Supplement). There were also 957,000 (95% UI, 871,000-1,030,000) deaths and 1.27 million (95% UI, 1.15-1.40 million) incident cases of stomach cancer in 2019 (Table 1). Stomach cancer was the leading cause of cancer incidence and mortality in 5 and 11 countries, respectively, for males (eFigures 5 and 6 in the Supplement) and of cancer mortality in 6 countries for females (eFigure 8 in the Supplement).

Breast cancer was the leading cause of cancer-related DALYs, deaths, and YLLs among females globally in 2019. Most of the global breast cancer burden occurred for females, with 20.3 million (95% UI, 18.7-21.9 million) of 20.6 million (95% UI, 19.0-22.2 million) total breast cancer-related DALYs in 2019 occurring in females, of which 93.3% (95% UI, 91.1%-95.2%) came from YLLs and 6.7% (95% UI, 4.8%-8.9%) from YLDs (eTable 14 and eFigure 4 in the Supplement). Likewise, 689,000 (95% UI, 635,000-740,000) of 701,000 (95% UI, 647,000-752,000) breast cancer deaths occurred in females, and 1.98 million (95% UI, 1.81-2.15 million) of 2.00 million (95% UI, 1.83-2.17 million) incident cases of breast cancer (Table 1). For females, breast cancer was the leading cause of cancer incidence in 157 countries and deaths in 119 countries (eFigures 7 and 8 in the Supplement).

Liver cancer was estimated to cause 12.5 million (95% UI, 11.4-13.7 million) DALYs in 2019; of these, 99.0% (95% UI, 98.6%-99.3%) came from YLLs and 1.0% (95% UI, 0.7%-1.4%) from YLDs (eTable 14 and eFigure 4 in the Supplement). There were also 485,000 (95% UI, 444,000-526,000) deaths and 534,000 (95% UI, 487,000-589,000) incident cases of liver cancer in 2019 (Table 1). Liver cancer was the leading cause of cancer incidence and mortality in 6 and 8 countries, respectively, in males (eFigures 5 and 6 in the Supplement) and 1 and 2 countries, respectively, in females (eFigures 7 and 8 in the Supplement).

Sex-specific DALY rankings differed slightly from those previously described because of the higher prominence of several sex-specific cancers. Among males, TBL cancer remained the leading cause of cancer-related DALYs globally, followed by stomach, CRC, liver, and esophageal cancer, with prostate cancer sixth (eFigure 9 in the Supplement). Among females, the leading cause of cancer-related DALYs globally was breast cancer, followed by TBL, CRC, cervical, and stomach cancer, with ovarian cancer sixth (eFigure 10 in the Supplement).

Global Trends in Cancer Burden From 2010 to 2019

Globally, the number of new cancer cases increased from 18.7 million (95% UI, 18.0-19.3 million) in 2010 to 23.6 million (95% UI, 22.2-24.9 million) in 2019, an increase of 26.3% (95% UI, 20.3%-32.3%). Age-standardized incidence rates remained generally the same during this period, with a difference of −1.1% (95% UI, −5.8% to 3.5%) and an annualized rate of change of...
<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Total Male</th>
<th>Total Female</th>
<th>Total Male</th>
<th>Total Female</th>
<th>Total Male</th>
<th>Total Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>10000</td>
<td>5690</td>
<td>4310</td>
<td>124.7 (116.4-132.0)</td>
<td>156.1 (143.9-167.2)</td>
<td>99.9 (91.5-107.3)</td>
</tr>
<tr>
<td>Excluding NMSC</td>
<td>9970</td>
<td>5650</td>
<td>4310</td>
<td>123.9 (115.7-131.2)</td>
<td>151.1 (142.9-166.1)</td>
<td>99.4 (91.0-106.6)</td>
</tr>
<tr>
<td>Tracheal, bronchus, and lung</td>
<td>2040</td>
<td>1390 (1260-1510)</td>
<td>657 (590-719)</td>
<td>25.2 (23.2-27.0)</td>
<td>37.4 (34.1-40.7)</td>
<td>15.0 (13.5-16.4)</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>1090</td>
<td>594 (551-638)</td>
<td>492 (483-532)</td>
<td>13.7 (12.6-14.5)</td>
<td>16.6 (15.4-17.9)</td>
<td>11.2 (10.0-12.2)</td>
</tr>
<tr>
<td>Stomach</td>
<td>957 (871-1030)</td>
<td>612 (544-678)</td>
<td>346 (308-382)</td>
<td>11.9 (10.8-12.8)</td>
<td>16.6 (14.8-18.3)</td>
<td>7.9 (7.1-8.8)</td>
</tr>
<tr>
<td>Breast</td>
<td>701 (647-752)</td>
<td>121 (107.3-133)</td>
<td>689 (635-740)</td>
<td>8.6 (7.9-9.2)</td>
<td>0.3 (0.3-0.4)</td>
<td>15.9 (14.7-17.1)</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>531 (492-567)</td>
<td>278 (258-299)</td>
<td>253 (226-274)</td>
<td>6.6 (6.1-7.1)</td>
<td>7.5 (7.0-8.1)</td>
<td>5.8 (5.1-6.2)</td>
</tr>
<tr>
<td>Esophageal</td>
<td>498 (438-551)</td>
<td>366 (315-415)</td>
<td>133 (110-150)</td>
<td>6.1 (5.4-6.8)</td>
<td>9.7 (8.3-11.0)</td>
<td>3.0 (2.5-3.4)</td>
</tr>
<tr>
<td>Prostate</td>
<td>487 (420-594)</td>
<td>487 (420-594)</td>
<td>NA</td>
<td>6.3 (5.4-7.7)</td>
<td>15.3 (13.0-18.6)</td>
<td>NA</td>
</tr>
<tr>
<td>Liver</td>
<td>485 (444-526)</td>
<td>334 (300-368)</td>
<td>151 (134-167)</td>
<td>5.9 (5.4-6.4)</td>
<td>8.7 (7.9-9.6)</td>
<td>3.5 (3.1-3.8)</td>
</tr>
<tr>
<td>Other malignant neoplasms</td>
<td>408 (355-444)</td>
<td>220 (180-249)</td>
<td>188 (169-204)</td>
<td>5.1 (4.5-5.6)</td>
<td>5.9 (4.8-6.7)</td>
<td>4.5 (4.0-4.8)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>335 (307-360)</td>
<td>188 (165-208)</td>
<td>146 (132-158)</td>
<td>4.3 (3.9-4.6)</td>
<td>5.2 (4.6-5.7)</td>
<td>3.5 (3.2-3.8)</td>
</tr>
<tr>
<td>Cervical</td>
<td>280 (239-314)</td>
<td>280 (239-314)</td>
<td>NA</td>
<td>3.4 (2.9-3.8)</td>
<td>6.5 (5.5-7.3)</td>
<td>566 (482-636)</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>255 (238-270)</td>
<td>146 (136-155)</td>
<td>109 (98.9-117)</td>
<td>3.2 (3.0-3.4)</td>
<td>4.0 (3.7-4.2)</td>
<td>2.5 (2.3-2.7)</td>
</tr>
<tr>
<td>Brain and central nervous system</td>
<td>246 (186-271)</td>
<td>139 (99.6-157)</td>
<td>108 (76.4-122)</td>
<td>3.0 (2.3-3.4)</td>
<td>3.6 (2.6-4.1)</td>
<td>2.5 (1.8-2.9)</td>
</tr>
<tr>
<td>Bladder</td>
<td>229 (211-243)</td>
<td>169 (157-181)</td>
<td>59.5 (52.3-64.6)</td>
<td>2.9 (2.7-3.1)</td>
<td>5.1 (4.7-5.4)</td>
<td>1.4 (1.2-1.5)</td>
</tr>
<tr>
<td>Lip and oral cavity</td>
<td>199 (182-212)</td>
<td>132 (118-145)</td>
<td>67.8 (60.8-75.7)</td>
<td>2.4 (2.2-2.7)</td>
<td>3.4 (3.1-3.8)</td>
<td>1.6 (1.4-1.7)</td>
</tr>
<tr>
<td>Ovarian</td>
<td>198 (175-218)</td>
<td>198 (175-218)</td>
<td>NA</td>
<td>2.4 (2.1-2.7)</td>
<td>4.6 (4.0-5.0)</td>
<td>294 (261-330)</td>
</tr>
<tr>
<td>Gallbladder and biliary tract</td>
<td>172 (145-189)</td>
<td>73.0 (59.5-80.4)</td>
<td>99.5 (81.7-114.0)</td>
<td>2.2 (1.8-2.4)</td>
<td>2.1 (1.7-2.3)</td>
<td>2.3 (1.9-2.6)</td>
</tr>
<tr>
<td>Kidney</td>
<td>166 (155-176)</td>
<td>109 (101-116)</td>
<td>57.7 (52.2-61.9)</td>
<td>2.1 (1.9-2.2)</td>
<td>3.0 (2.8-3.2)</td>
<td>1.3 (1.2-1.4)</td>
</tr>
<tr>
<td>Larynx</td>
<td>123 (115-133)</td>
<td>106 (97.8-115)</td>
<td>17.8 (16.2-19.7)</td>
<td>1.5 (1.4-1.6)</td>
<td>2.7 (2.5-3.0)</td>
<td>0.4 (0.4-0.5)</td>
</tr>
</tbody>
</table>

(continued)
Table 1. Global Incidence and Deaths in 2019 for Total Cancers and 29 Cancer Groups (continued)

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Total Male</th>
<th>Female</th>
<th>Total Male</th>
<th>Female</th>
<th>Total Male</th>
<th>Female</th>
<th>Total Male</th>
<th>Female</th>
<th>Total Male</th>
<th>Female</th>
<th>Total Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other pharynx</td>
<td>114 (88.0-98.7)</td>
<td>26.2 (22.5-30.5)</td>
<td>1.4 (1.2-1.5)</td>
<td>0.6 (0.5-0.7)</td>
<td>167 (153-180)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>0.9 (0.8-1.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>113 (109-117)</td>
<td>53.0 (45.1-58.3)</td>
<td>1.4 (1.2-1.5)</td>
<td>1.2 (1.0-1.3)</td>
<td>156 (137-173)</td>
<td>71.2 (60.3-80.1)</td>
<td>1.9 (1.7-2.1)</td>
<td>1.6 (1.4-1.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uterine</td>
<td>NA</td>
<td>2.1 (1.9-2.3)</td>
<td>0.6 (0.5-0.7)</td>
<td>167 (153-180)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>0.9 (0.8-1.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>71.6 (65.4-77.6)</td>
<td>20.4 (18.2-22.8)</td>
<td>0.9 (0.8-0.9)</td>
<td>0.5 (0.4-0.5)</td>
<td>177 (156-200)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>1.2 (1.0-1.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant skin melanoma</td>
<td>62.8 (46.3-71.0)</td>
<td>27.4 (19.0-31.9)</td>
<td>0.8 (0.6-0.9)</td>
<td>0.6 (0.4-0.7)</td>
<td>290 (214-342)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>1.2 (1.0-1.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonmelanoma skin cancer</td>
<td>56.1 (50.4-59.8)</td>
<td>22.8 (19.3-25.2)</td>
<td>0.7 (0.7-0.8)</td>
<td>0.5 (0.4-0.6)</td>
<td>6350 (5810-6950)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>1.2 (1.0-1.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>45.6 (41.3-48.8)</td>
<td>26.9 (23.7-29.3)</td>
<td>0.6 (0.5-0.6)</td>
<td>0.5 (0.5-0.6)</td>
<td>234 (212-253)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>1.2 (1.0-1.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>29.3 (26.7-31.0)</td>
<td>8.03 (5.88-8.92)</td>
<td>0.4 (0.3-0.4)</td>
<td>0.2 (0.1-0.2)</td>
<td>34.5 (31.2-37.8)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>1.2 (1.0-1.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>27.6 (23.7-31.8)</td>
<td>10.4 (8.23-12.6)</td>
<td>0.3 (0.3-0.4)</td>
<td>0.3 (0.2-0.3)</td>
<td>87.5 (77.9-101.4)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>1.2 (1.0-1.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testicular</td>
<td>10.8 (9.96-11.9)</td>
<td>10.8 (9.96-11.9)</td>
<td>0.1 (0.1-0.2)</td>
<td>0.3 (0.3-0.3)</td>
<td>109 (93.4-129.5)</td>
<td>37.6 (33.1-42.3)</td>
<td>2.0 (1.8-2.2)</td>
<td>1.2 (1.0-1.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ASIR, age-standardized incidence rate; ASMR, age-standardized mortality rate; NA, not applicable; NMSC, nonmelanoma skin cancer; UI, uncertainty interval.

Rows are ordered by decreasing number of total deaths. Cancer groups are defined based on International Classification of Diseases, Ninth Revision (ICD-9) and International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes and include all codes pertaining to malignant neoplasms (ICD-9 codes 140-208 and ICD-10 codes C00-C97) except for Kaposi sarcoma (C46, eAppendix in the Supplement). Tables 3 and 4 in the Supplement detail how the original ICD codes were mapped to the Global Burden of Disease cancer cause list. Visual comparisons of cancer-specific incidence and mortality are provided in eFigures 14 and 15 in the Supplement. Detailed results for incidence and mortality by Sociodemographic Index quintile, region, and country can be accessed in Tables 16 and 17 in the Supplement and at https://vizhub.healthdata.org/gbd-compare/.
Standardized mortality rates decreased in 131 countries and territories from 2010 to 2019 (95% UI, −11.9% to −1.1%) during this period.

In contrast, age-standardized mortality rates declined by −5.9% (95% UI, −11.0% to −0.9%) during this 10-year period, with a difference of −1.6% (95% UI, −7.7% to 4.6%) and an annualized rate of change of −0.2% (95% UI, −0.9% to 0.5%).

Similarly, the number of global total cancer deaths increased by 20.9% (95% UI, 14.2%-27.6%) from 8.29 million (95% UI, 7.89-8.57 million) in 2010 to 10.0 million (95% UI, 9.36-10.6 million) in 2019. Cancer deaths also increased as a proportion of total deaths of all causes, rising from 15.7% (95% UI, 15.0%-16.2%) in 2010 to 17.7% (95% UI, 16.8%-18.4%) in 2019. By contrast, age-standardized mortality rates declined by −5.9% (95% UI, −11.0% to −0.9%) during this 10-year period, with an annualized rate of change of −0.7% (95% UI, −1.3% to −0.1%). During this decade, the absolute number of global cancer-related DALYs increased by 16.0% (95% UI, 9.3%-22.8%) from 216 million (95% UI, 208-223 million) in 2010 to 250 million (95% UI, 235-264 million) in 2019. The proportion of estimated total global DALYs that were due to cancer increased from 8.4% (95% UI, 7.7%-9.0%) of total DALYs from all causes in 2010 to 9.9% (95% UI, 8.9%-10.9%) in 2019. A decline is also evident in the age-standardized rates, as age-standardized cancer-related DALYs decreased by −6.6% (95% UI, −11.9% to −1.1%) during this period.

Location-specific annualized rates of change in age-standardized mortality and incidence rates from 2010 to 2019 for total cancers, excluding NMSC, varied by location. During this period, age-standardized mortality rates decreased in 131 of 204 countries and territories (64.2%; Figure 3), and age-standardized incidence rates decreased in 75 of 204 countries and territories (36.8%; Figure 4).

Trends during the last decade varied by type of cancer, including several shifts in cancer group rankings by absolute DALYs (Figure 2). For example, CRC and liver cancer rose from the third and seventh leading causes of cancer-related DALYs in 2010 to second and fifth in 2019 because of large increases in the number of DALYs and small decreases in age-standardized DALY rates. In contrast, stomach cancer and leukemia dropped from second and third to seventh during the same period because of large decreases in age-standardized DALY rates and minimal changes in the number of DALYs (Figure 2).

Cancer Burden by SDI

Cancer burden varied considerably across SDI quintiles in 2019 levels and rankings (Table 2 and Figure 4) and trends during the 2010 to 2019 study period (Figure 5; eTables 16 and 17 in the Supplement). The following results exclude NMSC.

In the high SDI quintile in 2019, there were 50.9 million (95% UI, 48.1-52.9 million) DALYs estimated to be caused by cancer, of which 94.5% (95% UI, 93.1%-95.9%) were from YLLs and 5.5% (95% UI, 4.1%-6.9%) from YLDs. The most cases and the highest age-standardized incidence rates were in the high SDI quintile (Table 2; Figure 5). Compared with GBD level 2 groups of diseases and injuries, cancer was the leading cause of YLLs and DALYs in the high SDI quintile and was the leading or second leading cause of deaths by age-standardized rate or absolute number, respectively. In the high-middle SDI quintile, there were 63.5 million (95% UI, 58.6-68.2 million) DALYs estimated to be caused
by cancer, of which 96.7% (95% UI, 95.7%-97.6%) were from YLLs and 3.3% (95% UI, 2.4%-4.3%) from YLDs. The high-middle SDI had the highest age-standardized rates of deaths and DALYs of all SDI quintiles and the second highest age-standardized incidence rate (Table 2; Figure 5).

The middle SDI quintile had the highest number of cancer-related DALYs and deaths of any SDI quintile in 2019, with 76.3 million (95% UI, 69.7-83.2 million) DALYs and 2.88 million (95% UI, 2.62-3.15 million) deaths (Table 2, Figure 5). Of the SDI quintiles, the middle SDI quintile had the largest total population (eAppendix in the Supplement). For DALYs, 97.6% (95% UI, 96.8%-98.3%) came from YLLs and 2.4% (95% UI, 1.7%-3.2%) from YLDs. In the low-middle SDI quintile, there were 40.2 million (95% UI, 36.8-43.7 million) DALYs estimated to be caused by cancer in 2019; of these, 98.2% (95% UI, 97.7%-98.7%) were from YLLs and 1.8% (95% UI, 1.3%-2.3%) from YLDs.

In the low SDI quintile, there were 18.0 million (95% UI, 15.9-20.2 million) DALYs estimated to be caused by cancer in 2019; of these, 98.6% (95% UI, 98.1%-98.9%) were from YLLs and 1.4% (95% UI, 1.1%-1.9%) from YLDs. The low SDI quintile had the lowest numbers and age-standardized rates of cancer cases and deaths (Table 2; Figure 5). In contrast to the higher rankings in other quintiles, cancer was the fifth leading cause of death in the low SDI quintile in 2019, ninth for YLLs, and tenth for DALYs.

Alongside these differences, some patterns held across most SDI quintiles. In 2019, TBL cancer had the highest number of cancer deaths and DALYs in both sexes combined in all but the low SDI quintile, in which it was breast cancer (eFigure 11 in the Supplement). Excluding NMSC, the most incident cases occurred for CRC in the high SDI quintile, TBL in the high-middle and middle SDI quintiles, and breast cancer in the low-middle and low SDI quintiles (eFigure 12 in the Supplement).

While in 2019 the largest absolute numbers of cases and deaths occurred in the middle to high SDI quintiles, from 2010 to 2019, the largest increasing annualized rates of change in the absolute numbers of cases and deaths occurred in the low-middle SDI quintile and then the low SDI quintile (Figure 5; eTables 16 and 17 in the Supplement). Changes in age-standardized rates from 2010 to 2019 also varied by SDI quintile. For mortality, age-standardized rates increased from 2010 to 2019 in the low and low-middle SDI quintiles but decreased in the middle to high SDI quintiles. For incidence, age-standardized rates increased during this period for the low to middle SDI quintiles but decreased in the high-middle and high SDI quintiles, with the largest decrease in the high SDI quintile. While there was substantial heterogeneity between countries and territories within the same SDI quintile, country-specific estimates showed similar overall trends between SDI and age-standardized incidence and mortality rates (eFigure 13 in the Supplement).

Discussion

The results of this systematic analysis demonstrate the substantial and growing global burden of cancer, with patterns of
Figure 2. Cancer Group Rankings by Disability-Adjusted Life Years (DALYs) in 2019 and Percentage Change From 2010 to 2019

<table>
<thead>
<tr>
<th>Rank, Cancer</th>
<th>Absolute DALYs in 2019, millions (95% UI)</th>
<th>Percentage change in absolute DALYs, 2010-2019 (95% UI)</th>
<th>Age-standardized DALY rate in 2019, per 100,000 (95% UI)</th>
<th>Percentage change in age-standardized DALY rate, 2010-2019 (95% UI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Tracheal, bronchus, and lung cancer</td>
<td>45.9 (42.2 to 49.3)</td>
<td>18.1 (8.9 to 28.0)</td>
<td>551.6 (509.0 to 593.1)</td>
<td>-7.3 (-14.6 to 0.4)</td>
</tr>
<tr>
<td>2. Colon and rectum cancer</td>
<td>24.3 (22.6 to 25.7)</td>
<td>23.2 (16.3 to 30.2)</td>
<td>295.5 (275.2 to 313.0)</td>
<td>-2.7 (-8.1 to 2.8)</td>
</tr>
<tr>
<td>3. Stomach cancer</td>
<td>22.2 (20.3 to 24.1)</td>
<td>-0.5 (-9.3 to 9.2)</td>
<td>268.4 (245.5 to 290.6)</td>
<td>-20.8 (-27.7 to -13.3)</td>
</tr>
</tbody>
</table>

Rankings by absolute DALYs and exclude the other malignant neoplasms cancer group. Cancers are ordered by rank in 2019, with lines connecting to their rank in 2010. Absolute DALYs and age-standardized DALY rates for 2010 can be found online at https://gbd-data.sph.harvard.edu/gbd-compare/. Colors refer to the directional change in cancer rank from 2010 to 2019: red signifies an increase in rank, blue signifies no change in rank, and green signifies a decrease in rank. UI indicates uncertainty interval.

Figure 3. Annualized Rate of Change in Age-Standardized Total Cancer Incidence Rate From 2010 to 2019 in Both Sexes

Total cancer excludes nonmelanoma skin cancers. Annualized rate of change from 2010 to 2019 represents the average percentage change per year during this period, with negative values indicating decreasing incidence rates and positive values indicating increasing incidence rates. There were several geographic locations where estimates were not available (eg, Western Sahara and French Guiana), as they were not modeled locations in the Global Burden of Disease 2019 Study.
burden differing by SDI quintile. In 2019, cancer-related DALYs were second only to cardiovascular diseases in their contribution to global disease burden, and in the high SDI quintile, cancer overtook cardiovascular disease to become the leading cause of DALYs. Between 2010 and 2019, the number of new global cancer cases and deaths increased by 26.3% and 20.9%, respectively. However, the largest percentage increases in cancer incidence and mortality during the last decade occurred in the lower SDI quintiles, likely reflecting ongoing epidemiologic transitions, demographic shifts, and
disparities in cancer prevention, care, and control. Together, these results provide comprehensive and comparable estimates that can potentially inform efforts for equitably reducing the evolving burden of cancer globally.

While the absolute burden of cancer grew from 2010 to 2019, global age-standardized incidence rates remained similar at −1.1% (95% UI, −5.8% to 3.5%) and mortality rates decreased by −5.9% (95% UI, −11.0% to −0.9%). These age-standardized mortality results suggest cautious optimism that some progress may have been made in early diagnosis and cancer treatment globally during the last decade. However, inequalities in the distribution and growth of cancer burden around the world diminish this potential advancement and suggest that an acceleration of efforts to effectively address cancer burden are needed. Of particular concern, recent progress in reducing age-standardized incidence and mortality rates seems concentrated in higher SDI locations, while both rates are still trending upward in lower SDI locations. The increasing age-standardized incidence and mortality rates in lower SDI quintiles may reflect several factors, including shifting population age structures, increasing capacity for diagnosis and registration of cancer cases and deaths, and changes in cancer risk factors, such as metabolic, behavioral, environmental, and occupational exposures. For example, changing patterns of smoking prevalence by SDI quintile may be particularly relevant to cancer burden, with a need for further smoking reduction and tobacco control initiatives in many countries. These differences in cancer burden across the SDI spectrum suggest a need to tailor cancer control efforts to specific resource contexts and health system needs, incorporating local cultural and cancer context-specific knowledge.

Low and low-middle SDI locations had a higher rate of growth in the number of cases and deaths than high SDI locations during the last decade. Consistent with this trend, forecasts of cancer incidence and mortality suggest a growing burden in these locations, predicting that by 2040 more than two-thirds of the world’s cancers will occur in low-income and middle-income countries. Increasing cancer burden in already overburdened and underresourced settings is concerning given existing disparities in health care access and coverage. As many in countries within the lower SDI quintiles have insufficient access to cancer prevention services, timely diagnosis, and comprehensive treatment, efforts to strengthen cancer control infrastructure, expand workforce capacity, and increase access to universal health coverage and sufficient financial security will be crucial. The grouping of countries by SDI quintile is not meant to imply that all countries within an SDI quintile have equivalent capacity to prevent, diagnose, or treat cancers; each country has unique strengths and needs that should be considered. Further, the growing absolute number of cases and deaths in all SDI quintiles suggests that even as progress has been made in reducing age-standardized rates in some settings, globally there is an expanding need for health care infrastructure that is capable of supporting the provision of effective diagnoses and treatments for a growing number of patients with cancer.

While the traditional cancer metrics of incidence and mortality are crucial, DALY estimates provide perspective on the healthy years of life lost because of cancer morbidity and mortality globally. The GBD 2019 study found that on a global level, most cancer-related DALYs (96.9%; 95% UI, 96.0%-97.7%) in 2019 came from YLLs, suggesting that the total health loss from cancer was primarily associated with premature death. This finding is a valuable reminder of the lives that prematurely ended because of cancer globally and the importance of working toward improved global survival outcomes. While YLLs contribute less to global DALYs, the percentage of DALYs estimated to be caused by YLDs increased with increasing SDI quintiles, ranging from 1.4% (95% UI, 1.1%-1.8%) in the low SDI quintile to 5.7% (95% UI, 4.2%-7.1%) in the high SDI quintile. This greater comparative contribution of YLDs in higher SDI settings is consistent with likely improved survival, given generally more available access to cancer screening and diagnosis, treatment as SDI increases. Consequently, the contribution of YLDs to health loss due to cancer would be expected to be increasingly relevant to global health planning as cancer survival improves globally, and the support needs of survivors of cancer should be considered as part of comprehensive cancer control planning efforts.

The contribution of cancers to total global DALYs estimated to be caused by disease and injury has increased during the past decade, rising from third place in 2010 to second place in 2019, remaining behind only cardiovascular diseases. However, in high SDI settings, cancer-related DALYs have surpassed cardiovascular disease-related DALYs to become the leading cause of total disease burden in 2019. Other studies have described cancer’s emerging prominence as the leading cause of premature death in countries with high income or a high Human Development Index, some of which is attributed to relative decreases in cardiovascular disease deaths. The GBD 2019 study builds on this evolving global landscape of cancer burden by demonstrating the comparative importance of cancer in high SDI settings not just for mortality, but also when comparing the nonfatal burden of cancer and other diseases.

Together, these results suggest the need for increased cancer prevention and control efforts to reduce current burden, as well as the need to accelerate progress in lower SDI locations to reduce the effect of growing burden. One important step is bolstering national cancer control plans (NCCPs) that identify, plan, and evaluate a framework of cost-effective and feasible interventions, such as the World Health Organization’s best buys proposals for cancer prevention, diagnosis, and management. The increasing global uptake of NCCPs has demonstrated the utility of this approach in addressing cancer burden in several settings. However, creating and implementing effective NCCPs requires detailed knowledge about the local burden of cancer and associated risk factors, in addition to awareness of sociocultural circumstances and previous cancer control implementation efforts. Lack of information about local cancer epidemiology can be a substantial barrier in some data-sparse, and often resource-limited, locations. Cancer burden estimates, such as those in the GBD 2019 study, can potentially be helpful as part of context-specific cancer resource planning and prioritization efforts.
Conclusions

This systematic analysis of the GBD 2019 study provides comprehensive and comparable estimates of cancer burden worldwide, which were updated and improved from previous GBD cycles. These estimates varied substantially by SDI quintile, highlighting global inequities in cancer burden. While the high SDI quintile had the highest estimated number of incident cases in 2019, the middle SDI quintile had the highest estimated number of deaths and DALYS. During the last decade, cancer burden has grown the fastest in the low and low-middle SDI quintiles. Such estimates are vital for improving equity in global cancer outcomes and meeting key SDG targets for reducing cancer and other noncommunicable disease burden.
Iuliu Hatageiu University of Medicine and Pharmacy, Cluj-Napoca, Romania (Sur); Faculty of Health and Public Administration, Semmelweis University, Budapest, Hungary (Sóczka); Department of Medicine, University of Valencia, Valencia, Spain (Tabárés-Seisdedos); Carlos III Health Institute, Biomedical Research Networking Center for Mental Health Network, Madrid, Spain (Tabárés-Seisdedos); Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan (Tabun); Johns Hopkins University, Baltimore, Maryland (Tadibbi); Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran (Taherkanani); Pathology Department, Alexandria University, Alexandria, Egypt (Taalat); Department of Surgery, National University of Singapore, Singapore, Singapore (Tan); Department of Pathology, University of Texas, Galveston (Tat); College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Queensland, Australia (Tedla); University of Medical and Veterinary Sciences, Nigeria (Tedla); Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia (Tefera); Department of Community and Family Medicine, Iran University of Medical Sciences, Tehran, Iran (Tehrani-Banhashumi); Pediatric Intensive Care Unit, King Fahd Hospital of the University, Riyadh, Saudi Arabia (Temsah); School of Public Health, Mekele University, Mekele, Ethiopia (Tesfay); Southgate Institute for Health and Society, Flinders University, Adelaide, South Australia, Australia (Tesfay); School of Public Health, University of Adelaide, Adelaide, Australia, South Africa (Tessema); Division of Pediatric Gastroenterology, Case Western Reserve University, Cleveland, Ohio (Thavamani); Department of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona (Thoguluva Chandrasekar); Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, Vellore, India (Thomas-Hoat); HIV/STI Surveillance Research Center and World Health Organization Collaborating Center for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran (Tohidinik); Nutritional Epidemiology Research Team, National Institute for Health Research, Imperial College London, London, United Kingdom (Tabassian); School of Disability and Rehabilitation, Semmelweis University, Budapest, Hungary (Sóczka); Faculty of Medicine, University of Zagreb, Zagreb, Croatia (Tabacchi); School of Public Health, London, England (Tavoni-Palone); Modestum LTD, London, England (Tavoni-Palone); Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands (Traini); Department of Health Economics, Nantes University Medical School, Nantes, France (Traini); School of Psychology, University of Auckland, Auckland, New Zealand (K. B. Tran); Clinical Hematology and Toxicology, Maurice Wilkins Centre, Auckland, New Zealand (K. B. Tran); School of Public Health and Social Work, Queensland University of Technology, Brisbane, Queensland, Australia (M. T. N. Tran); Health Informatics, Nursing and Midwifery Faculty, Hanoi Medical University, Ha Noi, Vietnam (M. T. N. Tran); Department of Community Medicine, All India Institute of Medical Sciences, Nagpur, India (Tripathy); Department of Epidemiology and Biostatistics, Haramaya University, Haramaya, Ethiopia (Tusa); Department of Allied Health Sciences, Iqra National University, Peshawar, Pakistan (A. Ullah); Pakistan Council for Science and Technology, Ministry of Science and Technology, Islamabad, Pakistan (A. Ullah); Department of Pediatric Cardiology, Rush University, Chicago, Illinois (Umapathi); Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India (Unnikrishnan); Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India (Upadhay); Alzahra Teaching Hospital, Tabriz University of Medical Sciences, Tabriz, Iran (Vaezi); Women’s Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran (Vaezi); Clinical Cancer Research Center, Milad General Hospital, Tehran, Iran (Valadan Tahbaz, Yaghayadeh Jabbari); Department of Microbiology, Islamic Azad University, Tehran, Iran (Valadan Tahbaz); Department of Medical and Surgical Sciences and Advanced Technologies, University of Catania, Catania, Italy (Veroux); Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (Violante); Department of Medical and Surgical Sciences, Sant’Oroso Malghip Hospital, Bologna, Italy (Violante); Department of Health Care Administration and Economics, National Research University Higher School of Economics, Moscow, Russia (Vlassov); Faculty of Information Technology, University of Zilina, Slovakia (Zamarins); Division of Environmental Health, National Institute of Health, Lviv, Ukraine (Zastrozhin); Department of Neurosurgery, Erasmus University Medical Center, Rotterdam, Netherlands (Volovic); Center for Experimental Microsurgery, Iuliu Hatageiu University of Medicine and Pharmacy, Cluj-Napoca, Romania (Voloci); Cultures, Societies and Global Studies, Integrated Initiative for Global Health, Northeastern University, Boston, Massachusetts (Wama); School of Public Health, University of Nairobi, Nairobi, Kenya (Wama); College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia (Ward); Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, Stomatological Hospital (College) of Xi’an Jiaotong University, Xi’an, China (Wen); Competence Center for Mortality Follow-up of the German National Cohort, Federal Institute for Population Research, Wiesbaden, Germany (Winkler); Institute of Health and Society, University of Oslo, Oslo, Norway (Winkler); Department of Neurology, Technical University of Munich, Munich, Germany (Winkler); Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia (Yadav); Research and Development Division, The George Institute for Global Health, New Delhi, India (Yadav); Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, British Columbia, Canada (Yang); Division of Oncology, University of Calgary, Calgary, Alberta, Canada (Yang); School of International Development and Global Studies, University of Ottawa, Ottawa, Ontario, Canada (Yaya); George Institute for Global Health, University of Oxford, Oxford, England (Yaya); Department of Pharmacy, Debre Tabor University, Debre Tabor, Ethiopia (Yazie); Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia (Yezew); Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan (Yomoto); Department of Public Health, Juntendo University, Tokyo, Japan (Yomoto); Department of Health Policy and Management, Jackson State University, Jackson, Mississippi (Younis); School of Medicine, Tsinghua University, Beijing, China (Younis); Department of Environmental Health, Mazandaran University of Medical Sciences, Babolsar, Iran (Youvati); Institute, Hacetpe University, Ankara, Turkey (Yuce); Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia (Yunusa); Epidemiology and Cancer Registry Sector, Institute of Oncology Ljubljana, Ljubljana, Slovenia (Zadnik); Shahroud University of Medical Sciences, Shahroud, Iran (Zahra); Laboratory of Genetics and Genomics, Moscow Research and Practical Centre on Addictions, Moscow, Russia (Zastrozhi); Addictionology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia (Zastrozhi); Pediatrics Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia (Zastrozhi); Department of General Practice, University of Melbourne, Melbourne, Victoria, Australia (Zhang); Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia (Zhang); Bone Marrow Transplantation Center, Zhejiang University, Hangzhou, China (Zhou); Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health Science Center at Houston, Houston (Zhu); Departamento de Saúde Coletiva, Braxilia University, Brasilia, Brazil (Zimmermann); Division of Hematology, School of Medicine, University of Washington, Seattle (Fitzmaurice); Division of Pediatric Hematology-Oncology, University of Washington, Seattle, Washington (Force).

Author Contributions: Drs Kocakiri and Force had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Murray and Force are co-senior authors.


research support from Jackson State University. No other disclosures were reported.

Funding/Support: The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation and the American Lebanese Syrian Associated Charities. Dr Alljundi acknowledges the Department of Health Policy and Management of Kuwait University and the International Centre for Casemix and Clinical Coding, National University of Malaysia for the approval and support to participate in this research project. Dr Bhaskar acknowledges institutional support from the NSW Ministry of Health and NW Health Pathology. Dr Barninghaus was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, which is funded by the German Federal Ministry of Education and Research. Dr Brathwaite acknowledges funding from the National Institutes of Health/National Cancer Institute. Dr Conde acknowledges financial support from the European Research Council ERC Starting Grant agreement No 848325. Dr Costa acknowledges her grant (SRH/ BHD/10001/2019), received by Portuguese national funds through Fundação para a Ciência e Tecnologia, IP under the Norma Transitoria grant DL57/2016/CIP1334/C70006. Dr Githii acknowledges support from a grant from Novo Nordisk Foundation (NNF16OC021856). Dr Glasbey is supported by a National Institute of Health Research Doctoral Research Fellowship. Dr Vivek Kumar Gupta acknowledges funding support from National Health and Medical Research Council Australia. Dr Haque thanks Jazan University, Saudi Arabia for providing access to the Saudi Digital Library for this research study. Dr Hertel, Pan, and Ausodas are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. Dr Hugo received support from the Higher Education Improvement Coordination of the Brazilian Ministry of Education for a sabatical period at the Institute for Health Metrics and Evaluation, between September 2019 and August 2020. Dr Sheikh Mohammed Shaniful Islam acknowledges funding by a National Heart Foundation of Australia Fellowship and National Heart and Medical Research Council Emerging Leadership Fellowship. Dr Jakovljevic acknowledges support through grant OI 175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. Dr Katiirkeddi acknowledges funding from a NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02). The Medical Research Council (MC_UU_00022/0, and the Scottish Government Chief Scientist Office (SPhSUS/7)). Dr Md Nuruzzaman Khan acknowledges the support of Jatiya Kabi Kazi Nazrul Islam University, Bangladesh. Dr Yun Jin Kim was supported by the Research Management Centre, Xiamen University Malaysia (XUMRBF/2020-C6/ITCM/O004). Dr Koulmane Laximinarayana acknowledges institutional support from Manipal Academy of Higher Education. Dr Loureiro was supported by national funds through Fundação para a Ciência e Tecnologia under the Scientific Employment Stimulus-Institutional Call (CEECINST/ 0049/2018). Dr Molokha is supported by the National Institute for Health Research Biomedical Research Center at Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College London. Dr Mosavi-Dendel & Jeanney outside the submitted work. Dr Braithwaite reports research support from the National Institutes of Health/National Cancer Institute. Dr Catalá-López reports board service with the International Agency for Research on Cancer outside the submitted work. Dr Chatuvedi reports grants from the National Institutes of Health and government of India outside the submitted work. Dr Cortés reports research support from the Advanced Center for Chronic Diseases and Centro de Desarrollo Urbano Sustentable (Agencia Nacional de Investigación y Desarrollo Chile. Dr D’Arcy reports expert testimony in 2019 and board membership with the Expert Advisory Group of the Australian Mesothelioma Registry outside the submitted work. Dr El-Jaafari reports service on the steering committee of the Movement Disorder Society Young Members group. Dr Grosso reports research support from the University of Campania, Observatorio Epidemiologico Regionale and University of Catania and grants from the Italian Ministry of Health outside the submitted work. Dr Guha reports grants from the the American Heart Association. Dr Gunasekera reports service as an assistant secretary for Sri Lanka College of Obstetrics and Gynecology outside the submitted work. Dr Gupta reports grants from the National Health and Medical Research Council, Australia outside the submitted work. Dr Haider reports research support from Ohio University and board service for the American Public Health Association outside the submitted work. Dr Hertelu reports grants from the Romanian National Authority for Scientific Research and Innovation and Ministry of Labour and Social Justice, Romania outside the submitted work. Dr Hugo reports research support from CAPES Higher Education Improvement Coordination Brazil. Dr Kahnzi reports research support, grants, royalties/ licenses, consulting fees, honoraria, expert testimony, patents (planned, issued, or pending), board service, and stock and stock options from Razi University outside the submitted work. Dr G. Khan reports membership with the UAE Ministry of Health National Immunization Task Advisory Group. Dr Koul reports research support from Shenki Kashmire Institute of Medical Sciences. Dr La Vecchia reports grants or contracts from Associazione Italiana per la Ricerca sul Cancro outside the submitted work. Dr Miller reports grants from AIB InBex Foundation outside the submitted work. Dr Oduolaya reports grants from the National Institutes of Health. Dr Pana reports grants from the Romanian National Authority for Scientific Research and Innovation outside the submitted work. Dr Panagiotakos reports research support from the Hellenic Cardiology Society and Hellenic Atherosclerosis Society. Dr Sanabria reports research support from Melinda Gates Foundation, patents with their institution and board service for the Department and Surgical Services Lines outside the submitted work. Dr Silva reports research support from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brasil and CNPq. Dr Straif reports board service with the Collegium Ramazzini and ISEE Europe Chapter as an elected member and nonfinancial support from the International Agency for Research on Cancer outside the submitted work. Dr Volovic reports personal fees from JAMA Network Open. Dr Yazei reports research support from the Bill and Melinda Gates Foundation, American Lebanese Syrian Associated Charities, and St. Baldrick’s Foundation. Dr Younis reports research support from Jackson State University. No other disclosures were reported.

Funding/Support: The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation and the American Lebanese Syrian Associated Charities. Dr Alljundi acknowledges the Department of Health Policy and Management of Kuwait University and the International Centre for Casemix and Clinical Coding, National University of Malaysia for the approval and support to participate in this research project. Dr Bhaskar acknowledges institutional support from the NSW Ministry of Health and NW Health Pathology. Dr Barninghaus was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, which is funded by the German Federal Ministry of Education and Research. Dr Brathwaite acknowledges funding from the National Institutes of Health/National Cancer Institute. Dr Conde acknowledges financial support from the European Research Council ERC Starting Grant agreement No 848325. Dr Costa acknowledges her grant (SRH/ BHD/10001/2019), received by Portuguese national funds through Fundação para a Ciência e Tecnologia, IP under the Norma Transitoria grant DL57/2016/CIP1334/C70006. Dr Githii acknowledges support from a grant from Novo Nordisk Foundation (NNF16OC021856). Dr Glasbey is supported by a National Institute of Health Research Doctoral Research Fellowship. Dr Vivek Kumar Gupta acknowledges funding support from National Health and Medical Research Council Australia. Dr Haque thanks Jazan University, Saudi Arabia for providing access to the Saudi Digital Library for this research study. Dr Hertel, Pan, and Ausodas are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. Dr Hugo received support from the Higher Education Improvement Coordination of the Brazilian Ministry of Education for a sabatical period at the Institute for Health Metrics and Evaluation, between September 2019 and August 2020. Dr Sheikh Mohammed Shaniful Islam acknowledges funding by a National Heart Foundation of Australia Fellowship and National Heart and Medical Research Council Emerging Leadership Fellowship. Dr Jakovljevic acknowledges support through grant OI 175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. Dr Katiirkeddi acknowledges funding from a NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02). The Medical Research Council (MC_UU_00022/0, and the Scottish Government Chief Scientist Office (SPhSUS/7)). Dr Md Nuruzzaman Khan acknowledges the support of Jatiya Kabi Kazi Nazrul Islam University, Bangladesh. Dr Yun Jin Kim was supported by the Research Management Centre, Xiamen University Malaysia (XUMRBF/2020-C6/ITCM/O004). Dr Koulmane Laximinarayana acknowledges institutional support from Manipal Academy of Higher Education. Dr Loureiro was supported by national funds through Fundação para a Ciência e Tecnologia under the Scientific Employment Stimulus-Institutional Call (CEECINST/ 0049/2018). Dr Molokha is supported by the National Institute for Health Research Biomedical Research Center at Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College London. Dr Mosavi-Dendel & Jeanney outside the submitted work. Dr Pati acknowledges support from the SIAN Institute, Association for Biodiversity Conservation & Research. Dr Rakovac acknowledges a grant from the government of the Russian Federation in the context of World Health Organization Noncommunicable Diseases Office. Dr Samy was supported by a fellowship from the Egyptian Fulbright Mission Program. Dr Sheikh acknowledges support from Health Data Research UK. Drs Adithi Shetty and Unnikrishnan acknowledge support given by Kasturba Medical College, Mangalore, Manipal Academy of Higher Education. Dr Pavanchand H. Shingadia’s support.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official view of the Cancer Prevention and Research Institute of Texas.

Additional Contributions: We thank the many cancer registries around the world that worked to generate data on cancer burden.

Additional Information: Information about individual author contributions to the research is detailed in the eAppendix in the Supplement.

REFERENCES

6. NCD Countdown 2030 Collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress


